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Physiol. Rev. 79, Suppl.: S109-S144, 1999.-The pharmacology of cystic fibrosis transmembrane conductance regulator (CFTR) is at an early stage of development. Here we attempt to review the status of those compounds that modulate the Cl 0 channel activity of CFTR. Three classes of compounds, the sulfonylureas, the disulfonic stilbenes, and the arylaminobenzoates, have been shown to directly interact with CFTR to cause channel blockade. Kinetic analysis has revealed the sulfonylureas and arylaminobenzoates interact with the open state of CFTR to cause blockade. Suggestive evidence indicates the disulfonic stilbenes act by a similar mechanism but only from the intracellular side of CFTR. Site-directed mutagenesis studies indicate the involvement of specific amino acid residues in the proposed transmembrane segment 6 for disulfonic stilbene blockade and segments 6 and 12 for arylaminobenzoate blockade. Unfortunately, these compounds (sulfonylureas, disulfonic stilbenes, arylaminobenzoate) also act at a number of other cellular sites that can indirectly alter the activity of CFTR or the transepithelial secretion of Cl 0 . The nonspecificity of these compounds has complicated the interpretation of results from cellularbased experiments. Compounds that increase the activity of CFTR include the alkylxanthines, phosphodiesterase inhibitors, phosphatase inhibitors, isoflavones and flavones, benzimidazolones, and psoralens. Channel activation can arise from the stimulation of the cAMP signal transduction cascade, the inhibition of inactivating enzymes (phosphodiesterases, phosphatases), as well as the direct binding to CFTR. However, in contrast to the compounds that block CFTR, a detailed understanding of how the above compounds increase the activity of CFTR has not yet emerged.
I. INTRODUCTION
the different domains of CFTR interact to form a protein kinase A-and ATP-regulated Cl 0 channel; the mechanisms Experimentally, there is a considerable need for spe-of anion conduction; how CFTR interacts with other ion cific high-affinity ligands that could be used to probe the channels; the role CFTR plays in intracellular compartstructure and function of the cystic fibrosis transmem-ments to regulate pH, glycoprotein sulfation, and vesicle brane conductance regulator (CFTR). Insights gained fusion; as well as how mutations in CFTR cause cystic from such experimentation would allow us to better un-fibrosis (CF). Equally important will be the therapeutic derstand CFTR's role in cell biology, physiology, and ulti-impact of CFTR modulators in the treatment of respiramately the underlying mechanisms leading to clinical pa-tory disorders including CF, chronic obstructive pulmothology. There is little doubt that CFTR is the Cl 0 channel nary disease, asthma, bronchitis, emphysema, pneumonia that mediates cAMP-dependent Cl 0 secretion in various as well as secretory diarrhea, polycystic kidney disease epithelia. The availability of potent and specific CFTR and reproductive dysfunctions (congenital bilateral absence of the vas deferens, Ref. 270; testicular and sperm modulators would greatly aid our understanding of how S110 abnormalities, Ref. 88) . Compared with cation channels, nature has not been generous in providing Cl 0 channel modulators. Here we attempt to review the status of those compounds thought to interact with or modulate the Cl 0 channel activity of CFTR. The presentation is divided into two main sections discussing those compounds that block CFTR and those that open or increase the activity of CFTR.
The channel activity of CFTR can be altered at multiple levels (Fig. 1) . Because CFTR is activated by the cAMP signal transduction pathway, alterations in the binding of an agonist to its receptor, the G protein-mediated activation of adenylyl cyclase, the hydrolysis of cAMP by phosphodiesterase (PDE), and the activity of protein kinases or of protein phosphatases can influence the activity of CFTR. The opening and closing of CFTR is also dependent on ATP and ADP (sects. III and IV) and affected by the cellular redox potential (373) . Thus changes in cellular metabolism can influence the activity of CFTR. Therefore, a compound may act at one or more of these sites of action as well as bind directly to CFTR to alter channel tances such as members of the Cl 0 channel gene family (ClC) and voltage-and osmolyte-sensitive anion conductance have not historically received as much attention, macology of these compounds, specifically, the docuand thus their relative contribution to transepithelial ion mented actions of these compounds at sites other than movement remains to be defined (193, 399) . The activities CFTR. Our intent is to provide a basis upon which one of each of these basolateral and apical membrane transmay formulate an informed interpretation of the someporters and channels are tightly coordinated in the regutimes confusing array of published observations using lated secretion of Cl 0 . Thus, in addition to effects on the these compounds as well as to assist in the design of signal transduction pathways, compounds may have infuture studies with these compounds. hibitory or stimulatory effects on one or more of these
The pharmacology of CFTR is driven in large measure transporters and channels and thereby alter the secretion by the desire to develop agents that will be useful in the of Cl 0 . In general, many of the compounds that have been treatment of CF. Since the discovery of the gene coding used to alter the channel activity of CFTR are not specific for CFTR. We attempt, in this review, to present the phar-for CFTR (201, 302, 306) , over 700 mutations that cause S111 CF have been reported to the CF Genetic Analysis Consor-
The certainty that specific high-affinity CFTR channel modulators can be developed is supported by the pharmatium (13; accessible electronically at http://www.genet.-sickkids.on.ca). Mutations that cause one or more prob-cology of another member of the ABC transporter superfamily, the sulfonylurea receptor (SUR). The sulfonylurea lems in the transcription, translation, protein processing, or channel activity of CFTR have been described (394, receptor is found in pancreatic b-cells (2) and in muscle cells (185) , where it associates with Kir6.2 to form an ATP-395, 423, 424, 442) . The end result of the mutations in CFTR is an alteration in fluid and electrolyte transport in sensitive K / channel complex, K ATP (184). In this complex, SUR provides for both nucleotide and high-affinity sulfothe epithelia of the sweat glands, pancreas, intestines, reproductive organs, and airways. One approach to the nylurea sensitivity (146). The release of insulin from bcells can be modulated by sulfonylureas, several of which pharmacological treatment of CF is to restore normal function to the mutant CFTR protein. Although the debate bind to SUR with high affinity [e.g., dissociation constant (K D ) for glibenclamide õ1 nM]. The development of specontinues on how many functions CFTR serves, most investigators do agree the restoration of CFTR Cl 0 channel cific high-affinity compounds like glibenclamide for SUR required 27 years after the discovery of hypoglycemic activity in the apical membrane of the affected epithelia is a desired goal. Unfortunately, the vast majority of CF-drugs and the synthesis of at least 12,000 derivatives by numerous pharmaceutical companies (14, 41, 252) . A simicausing mutations result in the absence or reduced expression of apical membrane CFTR protein. Thus, for lar investment in effort may be required to obtain CFTR channel modulators of high potency and specificity. Cermost mutations, one must develop a pharmacological means of facilitating the transcription, translation, or pro-tain to be of importance will be a detailed understanding of the kinetics and mechanism of action of the candidate tein processing of CFTR to deliver a mature protein to the apical membrane. If, in addition, the mutation causes compounds affecting CFTR channel activity. The intent of this review is to present our current understanding of the channel to be dysfunctional, then the channel activity must also be pharmacologically modified to achieve nor-the mechanisms of action of those compounds now known to affect CFTR channel activity. Although there mal function. The deletion of phenylalanine at position 508 (DF508) in the first nucleotide binding fold (NBF) are only a few classes of compounds and fewer still to which a mechanism can be ascribed, the list is growing, is the single, most frequent CF-causing mutation, being present on Ç67% of mutant allels (193), although the rela-as is our understanding of their mechanisms of action.
Thus, although still in its infancy, the pharmacology of tive proportion of specific mutations varies depending on the population of inference (307). The DF508 mutation CFTR Cl 0 channels is progressing and is certain to yield significant future benefit. causes both protein processing and channel activity to be dysfunctional (85, 89, 103, 159, 178) . Therefore, the treatment of DF508 CF patients will require the correction II. CHANNEL BLOCKERS of both the protein processing and channel activity defects of the DF508 CFTR protein.
Although two entirely different classes of compounds A. Sulfonylureas and Diarylsulfonylureas may be required to restore normal function to DF508 CFTR,S113 (178, 322, 333, 428) , then sive site on SUR/Kir6.2, although the rank order of potency for glibenclamide and tolbutamide suggests that the the effect of the sulfonylureas would be to prolong the duration which CFTR remains in an activated state before sulfonylurea-sensitive site is weakly conserved.
Both glibenclamide and tolbutamide have been inactivation. All open-channel modulators would be expected to have similar effects on the state distribution, shown to reduce the open probability of CFTR in a structure-dependent and concentration-dependent manner by with the most potent compounds exhibiting the longest duration of interaction (i.e., the lowest k off ). Most effective direct interaction with the channel as recorded in cellfree membrane patches from CFTR-expressing C127 cells, in the symptomatic treatment of CF would be compounds that similarly decrease the inactivation rate by interacting Madin-Darby canine kidney (MDCK) cells, HEK 293 cells, and L cells (324, 331, 346, 409) . Inhibition of CFTR channel with the open state but maintain some ionic conduction.
Additionally, any such compound must, unlike glibencurrents in excised membrane patches of HT-29 cells, T84 cells (293) , and Xenopus oocytes (250) has also been re-clamide or tolbutamide, be shown to have a high degree of selectivity for CFTR (see below). ported. In each case, the effective concentration of glibenclamide was similar with the IC 50 or K D in the range of On the basis of the knowledge that sulfonylureas block CFTR by a direct interaction, it has become widely 2-30 mM. One discrepancy, however, is that reversal of effect with washout was rapid in mammalian expression accepted to employ glibenclamide-dependent inhibition of anion transport to indicate that CFTR participates in a systems (293, 324, 409 ) but failed to occur after an extended period in Xenopus oocytes (250 in intact tissues. Both nonunity Hill coefficients for coning, state and, in this linear scheme, reduces the likelihood of channel inactivation. The greater potency of gliben-centration-dependent inhibition and the inability to ''wash S114 out'' the inhibitory effect of glibenclamide might reflect pounds) make the diarylsulfonylureas attractive as lead compounds in the development of CFTR Cl 0 channel modconcerted effects on intracellular enzymes including PKA rather than an ongoing bimolecular interaction with CFTR ulators.
The mechanisms that communicate sulfonylurea or (90, 250, 347, 389). Likewise, a lack of effect or modest effect of glibenclamide can be misinterpreted to indicate diarylsulfonylurea binding to changes in CFTR channel gating remain to be determined. Although the CFTR chanthat CFTR is not present. Ionic, pH, or voltage conditions can be setup such that either CFTR or glibenclamide is nel protein is available and much is known about its nucleotide-and kinase-dependent regulation, pharmaceutical not in an optimal or permissive physicochemical confirmation for inhibition to occur (346) . Additionally, one compounds (and more importantly, a set of compounds known to interact with a common binding site) that regumust be especially careful in interpreting experiments employing õ30 mM glibenclamide, since, at these concentra-late its activity are not widely available. We have demonstrated specific binding of [ 125 I]iodoglibenclamide to tions, a significant block of CFTR would not be expected in any situation. Although glibenclamide can effectively CFTR (354) and have initial data to show that diarylsulfonylureas interact with this binding site in a structure-deblock CFTR and appears to be securely entrenched in CFTR literature, it is obvious that the field would benefit pendent way. Clearly, additional studies will provide insights to define the binding site and mechanism of action. from a more potent and selective inhibitor of CFTR.
Evidence from our laboratory indicates that diarylsul-Numerous parallels have been drawn between the pharmacology of CFTR, the SUR, and other ABC proteins. Like fonylureas provide greater selectivity and slightly higher potency than glibenclamide for the inhibition of CFTR CFTR, neither the sulfonylurea binding site on the SUR protein nor the mechanistic relationship between sulfo- (328, 329, 331) . The mechanism of action is identical to that presented above for glibenclamide and tolbutamide, nylurea binding and changes in K / channel activity is known. Mayorga-Ward et al. (241) have suggested that interaction only with the open state of CFTR channels to interrupt Cl 0 conduction. In contrast to glibenclamide, the glibenclamide binding site on Necturus intestine K / channels resides on or near the cytoplasmic face of the the diarylsulfonylureas have (by definition) substituted phenyl moieties linked to both the sulfonyl and urea of channel. Aguilar-Bryan et al. (2) reported that covalent modification of SUR with sulfonylurea ligands occurred the sulfonylurea backbone (Fig. 2) . The binding site of CFTR is like the SUR in that the pharmacophore does not within the amino-terminal third of the protein but that further identification of the binding site had not been comrequire an aromatic acid or aliphatic amine linked to the sulfonyl phenyl group for functional interaction, e.g., tol-pleted. Subsequently, a second SUR (SUR2) has been cloned which, when coexpressed with Kir6.2, exhibits butamide. A p-methyl substituent on the sulfonyl phenyl appears to be adequate for interaction with the binding pharmacological characteristics of cardiac or skeletal muscle K ATP (185). Because the affinity of this isoform site (329, 409), although compounds including either benzofuran (LY-295501; Fig. 2 ) or indanyl (LY-186641; Fig. 2 ) for glibenclamide is reduced (compared with SUR1) and because SUR are reported to have a single sulfonylurea groups linked to the sulfonyl have been shown to be effective (328) . Potency of CFTR inhibition varies over more binding site (146), sequence comparison or chimeric expression will likely provide indications of the binding site than three orders of magnitude depending on the ureaphenyl substituents. Electron-withdrawing substituents local. Continuing research on SUR/Kir6.2 and CFTR with this class of compounds will certainly produce SAR that (e.g., in Fig. 2 , R Å Cl, NO 2 , or CF 3 ) at the para-and/or meta-positions of the urea phenyl have been shown to will enlighten us regarding their mechanistic basis and direct the synthesis of more potent, selective, and thus provide for higher affinity interactions than electron-donating or electroneutral substituents (e.g., R Å OH or more useful compounds as we attempt to understand and modulate the many functions of CFTR. H) (329 (Fig. 2) as a general fluorescent, impermeant covalent modifier of membrane (328) , and not to affect the SUR/Kir6.2, in vivo, as assessed by the failure to affect blood glucose levels in rats (171) . amino groups. Subsequently, SITS and other stilbene disulfonates (25) were recognized as novel inhibitors of That diarylsulfonylureas might be safely administered to humans is evidenced by the fact that both LY-186641 and band 3-mediated Cl 0 /HCO 0 3 anion exchange in human red blood cells (206) . Much of the work done in understanding LY-295501 have been employed in clinical trials (196, 271, 420; S. Beardslee, personal communication). These attri-the reversible nature of inhibition by SITS revealed that the blockade of anion transport was not the result of butes (a partially defined mechanism of action on CFTR, a unique SAR, and clinical safety of closely related com-intrinsic chemical modification, but rather of an ''explicit'' S115 interaction between the disulfonic stilbene probe and an also fails to block CFTR-mediated whole cell Cl 0 currents (83, 99, 139, 140, 265, 300, 309, 336, 371, 372, 384, 403 , apparent binding site (58) . Since then, several purely noncovalent reversibly acting (e.g., 4,4-dinitrostilbene-2,2-431). Indeed, CFTR is one of the very few Cl 0 channels that is not blocked by extracellular DIDS. The disulfonic disulfonic acid, DNDS; Fig. 2 ) and covalent irreversibly acting (e.g., DIDS; Fig. 2 ) disulfonic stilbene derivatives stilbenes do block CFTR from the intracellular side (see below) but, because the sulfonate groups of the disulfonic have been designed and synthesized (58) (59) (60) . These agents have played a critical role in the definitive identifi-stilbenes are present as fully ionized divalent anions at physiological pH (57), they do not penetrate the plasma cation of the anion exchanger protein band 3 (58-60, 222, 441) .
membrane. The disulfonic stilbenes, preferably DNDS, could be used diagnostically to implicate CFTR-mediated The disulfonic stilbenes are among the most potent inhibitors of band 3-or AE1 (anion exchanger)-mediated Cl 0 secretion. However, because one anticipates a negative result from this type of experiment, additional posi-(6) anion exchange. The inhibitory constants (IC 50 ) of various disulfonic stilbene derivatives for AE1 span a concen-tive controls are needed before one can conclude Cl 0 secretion is mediated by CFTR. tration range of over four orders of magnitude (0.8-500 mM, Ref. 57) . Disulfonic stilbenes also inhibit the recently Although the disulfonic stilbenes do not appear to directly block CFTR from the extracellular side, they may cloned AE2 and AE3 anion exchangers found in a variety of tissues (7, 87, 213, 216, 226) . The backbone of this class by indirect means influence CFTR-mediated Cl 0 secretion. DIDS has been reported to increase short-circuit current of inhibitor consists of a trans-2,2-disulfonic stilbene structure, with varying 4,4-substituents (26, 58). A quanti-and serosal-to-mucosal Cl 0 fluxes across stripped rabbit colonic mucosa (364). Basolateral addition of DIDS or tative SAR of disulfonic stilbene derivatives revealed that there is a positive correlation with the Hamett constant SITS at a concentration between 10 and 200 mM has been reported to produce a transient increase in short-circuit (s, a measure of the capacity to exchange electrons), and the Hansch constant (p, a measure of hydrophobicity) of current, which was followed by a gradual inhibition across T84 monolayers (48) . This transient stimulation with DIDS the 4,4-substituents. The reversible type of inhibition has been studied dynamically using various techniques such was also observed for whole cell Cl 0 currents in isolated T84 cells grown on permeable supports as well as the as spectrophotometry (111, 126), fluorimetry (58, 283, 412) , and NMR (117, 130), or by utilizing radioactively human airway cell line Calu-3 (360) and was attributed to the elevation of cytosolic Ca 2/ levels. Although the exact labeled forms of disulfonic stilbenes (58-60, 222, 351) . On the other hand, the irreversible type of binding with mechanism by which DIDS increases Ca 2/ levels is not known, the fact remains that the disulfonic stilbenes are membrane components has been studied by radioactively labeled forms of disulfonic stilbenes or by Western blot-capable of elevating cytosolic free Ca 2/ in both confluent as well as nonconfluent T84 epithelial cells (48) . The ting (57) . Despite the advantages of using disulfonic stilbene derivatives with noncovalently reactive 4,4-substitu-mechanistic basis for the gradual decrease in short-circuit current in T84 cells by the disulfonic stilbenes is also tions (e.g., DNDS), most studies have used the covalently reactive derivatives DIDS or SITS. The quality of commer-unknown but might result from alteration in intracellular pH due to the inhibition of anion exchange. Disulfonic cially available DIDS and SITS is not uniform, because some companies provide them as free acids and others stilbenes have also been shown to effect various epithelial K / channels such as I SK (55, 342, 407) , K ATP (128) , and the as sodium salts with varying degrees of cis/trans-isomerization and different ratios of NCS and NH 2 groups. Be-Ca 2/ -activated K / channel in smooth muscle cells (167) . A disulfonic stilbene-sensitive epithelial Cl 0 channel cause of the hygroscopic properties and tendency or ease of intermolecular reactions of the NCS group with NH 2 that has received considerable attention by CF investigators is the ORCC. DNDS reversibly blocked the ORCC groups, especially with sodium salts of the disulfonic stilbenes, polymerization can occur yielding DIDS-DIDS, incorporated into planar lipid bilayers with a K D of [2] [3] mM when applied to the extracellular side, and DIDS DIDS-4,4-diaminostilbene-2,2-disulfonic acid (DADS) (Fig. 2) , and DIDS-DADS-DIDS polymers. As suggested by caused an irreversible inhibition (49, 353) . Structure-activity studies with the disulfonic stilbenes and a structurally Racker (294) ''DIDS which often 'dids' more than advertised'' should be used with caution. similar class of compounds, the sulfonated calixarenes, have led to the development of a highly potent blocker The disulfonic stilbenes, most often DIDS, have been shown to block a wide variety of Cl 0 channels expressed (K D Å 0.6 nM) of ORCC, TS-TM-calix [4] arene (5,11,17,23-tetrasulfonato-25,26 ,27,28-tetramethoxy-calix [4] arene; in numerous cell types (1, 17-19, 38, 42, 43, 47, 71, 72, 96, 101, 136, 138, 160, 190, 191, 200, 204, 205, 224, 225, 255, Fig. 2 (49, 340) . Extracellular DIDS it has been suggested that CFTR regulates ORCC and that S116 both channels may contribute to transepithelial Cl 0 secre-353) and may interfere with the cAMP signal transduction cascade (166, 214, 426) , thus complicating the interpretation (179, 335, 336 (382) have suggested that R347 contributes to an important anion-binding site close to the cytoplasmic end of by Schwiebert and co-workers (335, 336) are due to the blockade of ORCC or an antagonism at the ATP receptor. the channel pore. Linsdell and Hanrahan (228) suggest that CFTR channel pore may contain a relatively large In the studies by Hwang et al. (179) , mucosal DIDS blocked the stimulation in short-circuit current by muco-inner vestibule accessible from the intracellular side to large blocking anions such as DNDS, gluconate, and glutasal ATP but did not block stimulation by serosal ATP. These results support the notion that DIDS may be acting mate and that arginine-347 may be involved in anion binding within this region of the pore. Further structure-activat a purinergic receptor, since mucosal DIDS will not have access to a basolateral membrane purinergic receptor but ity studies with additional disulfonic stilbenes and perhaps calixarene derivatives together with additional will have access to an apical membrane purinergic receptor. On the basis of the very close structural similarity mutational analysis will be useful in defining the CFTR structure at this site as well as the development of higher between TS-TM-calix [4] arene and the disulfonic stilbenes, the inhibitory effects of the calixarene may also be due affinity blockers of CFTR. to ATP receptor antagonism. Second, we (357) and others have failed to see an inhibitory effect of the disulfonic C. Arylaminobenzoates stilbenes or TS-TM-calix [4] arene on transepithelial Cl 0 secretion in a variety of secretory epithelia including primary cultures of rat tracheal epithelial cells stimulated
The arylaminobenzoate DPC ( (179), we suggest that the inhibitory effects of DIDS in their studies may have an alternative explanation and Cl 0 conductance of shark rectal gland tubules (RGT). The DPC had an IC 50 of 26 mM when added to the basolateral that ORCC does not contribute to transepithelial Cl 0 secretion. Glibenclamide and diphenylamine-2-carboxylate side of the rabbit cortical and mouse medullary portion of the TAL (cTAL and mTAL, respectively), both of which (DPC) were also used in these studies with the intention of discriminating between CFTR and ORCC. Unfortu-are NaCl-reabsorptive epithelia (163, 164, 417) . When added to the apical side in the RGT, a NaCl-secreting nately, glibenclamide and DPC also block ORCC (293, 324, S117 epithelia, DPC showed similar inhibition of the apical side of the channel, so cytosolic addition precludes NPPB reaching its interaction site. However, apart from being membrane Cl 0 conductance (143, 144, 157). The inhibition by DPC on both the renal and rectal gland epithelia was anions, with pK values of 3-5, the arylaminobenzoates are lipophilic. At a pH of 7.4, Ç50-90% are distributed shown to be rapid and reversible. Di Stefano et al. (100) have shown the presence of a DPC (100 mM)-sensitive into the lipid phase, e.g., DPC has a partition coefficient of 0.58 (water/CH 2 Cl 2 ) (100), so by the addition of these Cl 0 channel in excised inside-out patches from the apical membrane of RGT and the basolateral membrane of rabbit compounds on one side of the cell membrane, one cannot rule out their penetration across the cell membrane. IncTAL; however, the concentration dependence of DPC block was not evaluated. An SAR of 219 arylaminoben-deed, we have demonstrated that both DPC and NPPB showed similar inhibition from the extracellular and intrazoates led to the discovery of more potent blockers such as NPPB (Fig. 2) , which inhibited the basolateral mem-cellular sides of the ORCC incorporated into planar lipid bilayer with K i values of 600 and 25 mM, respectively (353). brane Cl 0 conductance of cTAL with an IC 50 of 80 nM (416). To our knowledge, the single-channel identity of a
The concentrations at which the arylaminobenzoates DPC and NPPB have been used in different studies do Cl 0 channel with an IC 50 of 26 mM for DPC or 80 nM for NPPB has not been shown in the cTAL or any other raise a question about their specificity to inhibit one type of Cl 0 channel as compared with other channels or intraepithelia.
Since the discovery of the arylaminobenzoates, high cellular processes. The arylaminobenzoates share some structural similarity with loop diuretics. In the first paper concentrations of DPC and NPPB have been widely used in several macroscopic assays as inhibitors of Cl 0 trans-describing the SAR of this class of compounds, it was shown that some of the arylaminobenzoates also had an port in numerous epithelia (57) . These include rabbit, canine, and sheep tracheal epithelia (189, 374) , luminal affinity for the Na / channels in (intestine 407) (215), retinal pigment epithelial cells (174, 398) , cultured human airway epithelial cells (242, 336) , HT-29/B6 cells (180) , an inwardly rectifying Ca 2/ -dependent K / channel in turtle colon (301) , and a Ca 2/ -and human pancreatic duct cells (411) , rabbit colonic epithelia (142) , mouse muscle cells (142, 414) , and cultured human cAMP-activated low-conductance K / channel in the basolateral membrane of human colonic crypt cells (229) . It biliary cells (305) . In all of these studies, the concentrations used were considerably higher than required to in-is especially important to consider the inhibition of basolateral membrane K / channels and the basolateral memhibit the Cl 0 conductive pathway across cTAL and RGT, although the inhibition of Cl 0 transport was considered brane cotransporter by these compounds when studying Cl 0 secretion. In a typical Cl 0 secretory epithelia, the apito result from the blockade of Cl 0 channels. With the use of several microscopic assays such as cal membrane Cl 0 conductance and the basolateral membrane K / conductance are tightly coupled to maintain a planar lipid bilayer and excised membrane patches, DPC and NPPB have been shown to inhibit endogenous and sustained level of Cl 0 secretion. Inhibition of either apical membrane Cl 0 channels, basolateral membrane K / chanheterologously expressed Cl 0 channels in several epithelial cells. These include the ORCC from the human carci-nels, or the basolateral membrane cotransporter will inhibit Cl 0 secretion. Hence, where investigators have innoma cell line HT-29 (102, 161), rat colonic enterocytes (353), and cultured human respiratory cells (217), a Ca 2/ -tended to used DPC as an inhibitor of apical membrane CFTR to differentiate between cAMP-activated Cl 0 secredependent Cl 0 channel from sheep airway epithelium (8, 9), volume-sensitive outwardly rectifying Cl 0 channels tion via CFTR and other Cl 0 channels, there could well have been an inhibition of the basolateral membrane K / from various epithelia (1, 17, 71, 72, 138, 215, 242) , and CFTR in various epithelia (see below). Tilmann et al. (387) conductances or cotransporter that is the actual cause of the inhibition of Cl 0 secretion. have shown that NPPB inhibits an ORCC from HT-29 cell line with a K i of 0.9 mM when added to the cytosolic side Diphenylamine-2-carboxylate, NPPB, and some other arylaminobenzoates have been shown to have considerand a K i of 0.1 mM when added to the outer membrane side of the channel. The reason for this difference in the able inhibitory effects on intracellular adenylyl cyclase in the Cl 0 secretory human colonic cell lines HT-29/B6 and K i values was attributed to the fact that the NPPB interaction site is likely accessible only from the extracytosolic T84 (166, 214, 426) . Kreusel et al. (214) have shown that S118 1 mM DPC inhibited ú85% of forskolin (10 mM)-activated dependence of the blockade and the Woodhull equation (433), the K D for DPC at 0 mV was 912 mM and at 100 mV cAMP production in HT-29/B6 cells. Diphenylamine-2-carboxylate was unable to inhibit Cl 0 secretion activated by was 237 mM. Similarly, the K D for FFA at 0 mV was 1.22 mM and at 100 mV was 289 mM. The apparent electrical dibutyryl cAMP. In a similar study with the T84 cell line, 500 mM DPC or NPPB inhibited forskolin-stimulated distance sensed by both the blockers was 41% as measured from the inside of the membrane. The studies of cAMP production by 28 and 56%, respectively (166) . Thus it is possible that the mechanism of action of DPC in this McDonough et al. (245) extended these findings to demonstrate that the interaction of DPC with CFTR was consisand other cellular-based studies results from the inhibition of cAMP production rather than a direct inhibition tent with an open-channel mechanism of blockade. Furthermore, site-directed mutagenesis of residues in the on Cl 0 channels. Diphenylamine-2-carboxylate has also been reported to inhibit prostaglandin D 2 synthesis from putative transmembrane segments (TM) 6 and 12 significantly altered DPC blockade of the channel. Most notably, arachidonic acid in primary cultures of canine tracheal epithelium (375) . The likely site of action of DPC in this mutation of serine-341 to an alanine caused a fivefold increase in the K D at 0100 mV (wild type, 276 mM vs. tissue is the inhibition of cyclooxygenase, the enzyme responsible for prostaglandin synthesis. Prostaglandins S341A, 1,251 mM). This result is of special interest, since the predicted position of residue 341 lies 40% through the are important modulators of electrolyte transport in a number of epithelia (33, 233, 237, 262, 292, 295, 365, 391, proposed TM6. Although S1141 in TM12 is predicted to have a similar position as S341 in TM6, mutation of serine-413). Thus the arylaminobenzoates appear to inhibit both the cAMP and eicosanoids signal transduction pathways. 1141 to an alanine did not show an appreciable effect on DPC binding. Furthermore, when the methionine and The arylaminobenzoates have also been shown to have profound effects on intracellular pH in LLC-PK 1 cells (50) threonine residues immediately adjacent to S1141 were changed to isoleucine and phenylalanine to match the and could thereby modulate a number of intracellular processes and channel activities. The interpretation of ar-residues immediately adjacent to S341, DPC bound with an affinity close to that of the wild-type channel (S341A-ylaminobenzoate inhibition of macroscopic Cl 0 secretion is, at best, difficult because of their nonselectivity for Cl 0 M1140I-T1142F). This showed that the DPC-binding site on TM6 could be transferred to TM12. Mutation of threochannels coupled with their inhibition of basolateral membrane K / channels and the Na / -K / -2Cl 0 cotransporter. nine residue 1134 to a phenylalanine caused a threefold improvement in the affinity for DPC (T1134F, 74 mM). Like As with the disulfonic stilbenes, the use (abuse) of the arylaminobenzoates as Cl 0 channel blockers has become residue 341, residue 1134 lies 40% through the proposed TM12. These results strongly support the notion that both entrenched in the literature. Clearly, more specific reagents are needed to study the contribution of CFTR in TM6 and TM12 contribute to forming the pore. They speculated that the carboxy group of DPC interacted with S341 anion secretion by intact epithelia.
Caution aside, DPC and NPPB have been shown to on TM6 and the phenyl ring with T1134 on TM12. (243) demonstrated that DPC and flufenamic acid (FFA; use these small ligands to probe the structure and kinetics of CFTR channel activity. 3-trifluoromethyldiphenylamine-2-carboxylic acid; Fig. 2 ) blocked CFTR-mediated whole cell and single-channel Cl 0 currents in Xenopus oocytes. Blockade was voltage de-III. CHANNEL OPENERS pendent; currents at positive potentials were not affected, but currents at negative potentials were blocked. Both DPC and FFA blocked single-channel openings in an ex-A. Xanthines cised patch when applied directly to the cytoplasmic side of the channel. As expected from the whole cell data, DPC Paleolithic man is credited with the discovery of the central nervous system (CNS) stimulatory effects of and FFA blockade of CFTR in excised patches was also voltage dependent. The onset of blockade by extracellu-drinks made from alkylxanthine (caffeine, theophylline, theobromine; Fig. 3 ) containing plants (coffee, tea, cocoa) larly applied DPC or FFA was biphasic, with an early rapid phase and a later phase that developed over several (303). Alkylxanthines are now known, in addition to their CNS effects, to relax smooth muscle, most notably bronminutes. The slow development of the blockade was attributed to the permeation of the blocker into the cell to chial smooth muscle, stimulate cardiac muscle, and act on the kidney to cause diuresis. The treatment of asthmatic an intracellular binding site on CFTR. Blockade by DPC and FFA was fully reversible. With the use of the voltage patients with strong coffee was initiated more than 100 years ago (314) . Recent clinical studies suggest CF pa-the formation of cAMP and the activation of PKA. Soon after its discovery, CFTR was shown to be a PKA-actitients may also benefit from the use of bronchodilators such as the alkylxanthines (82). The cellular sites of action vated ATP-dependent Cl 0 channel as reviewed in detail in References 129a and 333a. Salient to CFTR activation of the alkylxanthines include the mobilization of intracellular Ca 2/ (115), the inhibition of phophodiesterases (28), by alklyxanthines, McPherson et al. (251) were the first the inhibition of phosphatases (81, 118), and the blockade to demonstrate that IBMX partially restored amylase and of adenosine receptors (192) . Adenosine receptor block-mucin secretion in submandibular acinar cells from CF ade is thought to be the relevant site of action at dietarily patients. Subsequently, Drumm et al. (103) were the first achieved alkylxanthine concentrations (50 mM). Ten-to to show that CFTR constructs with naturally occurring 20-fold higher concentrations of caffeine or theophylline mutations in the first NBF could be activated by high are required to increase intracellular Ca 2/ or inhibit PDE. concentrations of IBMX. In their studies, Xenopus oocytes The inhibition of PDE to elevate cAMP levels has been were injected with wild-type or mutant CFTR (e.g., the often intended reason for using alkylxanthines, espe-DF508, G551D) mRNA, and Cl 0 current was measured in cially 3-isobutly-1-methyxanthine (IBMX; Fig. 3 ), in epithe-response to a stimulation cocktail including 10 mM forlial transport studies. However, Becq and co-workers (29, skolin, 200 mM 8-(4-chlorophenylthio)-cAMP, and various 30) have also made use of the phosphatase inhibitory ef-concentrations of IBMX. Mutant CFTR were less sensitive fects of IBMX to study the phosphorylation-dependent than wild-type CFTR to IBMX. For example, oocytes exregulation of CFTR.
pressing wild-type CFTR were nearly completely stimulated with 1 mM IBMX, but those expressing G551D or The cAMP-mediated activation of Cl 0 secretion has been recognized for more than 30 years (24, 154) and the DF508 CFTR required 5 mM IBMX to achieve complete stimulation. The reduction in sensitivity of the mutant failure of CF epithelia to respond to cAMP for nearly 20 years. Studies before the discovery of CFTR demonstrated CFTR was also found to be correlated with the severity of the CF in patients carrying the corresponding mutations. the impaired responsiveness of CF epithelia lies distal to S120 The differential sensitivity of CFTR bearing muta-mary epithelial cells (C127 cells) expressing DF508 CFTR. Haws et al. (159) also demonstrated, with patch-clamp tions in NBF1 or NBF2 to IBMX stimulation was further evaluated by Smit et al. (362) . Mutation of a conserved studies, that DF508 CFTR was present in the plasma membrane albeit at a lower channel density than wild-type glycine (G551 and G1349) in the putative linker domains of either NBF reduced the sensitivity to IBMX, and muta-CFTR-expressing cells and with a lower open probability (P o ) of 0.11 compared with wild-type CFTR (P o Å 0.33). tions of this site in both NBF produced an additive effect. In contrast, substitutions in the Walker A and B motifs Beavo (28) has provided a recent review of the cyclic nucleotide PDE. An estimated 25 PDE isoforms are produced strikingly different effects in NBF1 and NBF2. Substitutions for the conserved lysine (K464, Walker A) or thought to exist. The pharmaceutical industry has attempted to capitalize on the tissue-specific expression of asparate (D572, Walker B) in NBF1 resulted in a marked decrease in sensitivity to IBMX, whereas the same the various PDE isoforms in the development of antiasthmatic, antithrombotic, antihypertensive, cardiotonic, and changes in NBF2 (K1250, Walker A; D1370, Walker B) produced an increase in sensitivity. Smit et al. (361) went antidepressant agents. There are, as a result of these drug development efforts, a number of isoform-specific PDE on to show that the missense mutation G480C associated with CFTR protein mislocalization was equally sensitive inhibitors that are in clinical use. Kelly et al. (198) set out to determine which of the specific classes of PDE were to IBMX stimulation when compared with wild-type CFTR. Wilkinson et al. (428) undertook a quantitative involved in the activation of CFTR in epithelial cells. Milrinone and amrinone (Fig. 3) , class III PDE inhibitors, were analysis of the rates of activation and inactivation of these same mutants in response to stimulation and removal of found to stimulate 125 I efflux in Calu-3 and 16HBE human airway epithelial cells, whereas the class IV PDE inhibitor 10 mM forskolin and 5 mM IBMX. Consistent with the steady-state current measurements of their previous stud-rolipram and the class V PDE inhibitor dipyridamole were much less effective. Stimulation of 125 I efflux by milrinone ies, substitutions at G551 in NBF1 or G1349 in NBF2 reduced the rate of activation and increased the rate of and amrinone did not require the inclusion of an adenylyl cyclase activator (e.g., forskolin), nor did stimulation corinactivation. Substitutions at K464 or K1250 also reduce the rate of activation but had opposite effects on the rate relate with cAMP levels. However, stimulation by milrinone and amrinone was inhibited by the cell-permeant of inactivation; K464 substitution increased the rate of inactivation while K1250 substitution decreased the rate PKA
inhibitor N-(2-[methylamino]ethyl)-5-isoquinoline-
sulfonamide (H-8) and the cAMP antagonist R p -cAMP. of inactivation. Substitutions of D572 decrease the rate of activation and increased the rate of inactivation. In These results are consistent with a cAMP/PKA-mediated activation of CFTR that results from a compartmentalized contrast, D1370 substitutions did not alter the activation rate but markedly slowed the inactivation rate. Thus pool of cAMP. These studies were extended to show that 36 Cl efflux could be stimulated by milrinone plus isopro-D1370 mutants remained active long after the removal of the stimulation cocktail. These elegant macroscopic terenol in the transformed nasal polyp cells (CF-T43) homozygous for DF508-CFTR (197) . The CFTR antisense measurements demonstrated that mutations in either NBF1 or NBF2 can influence the activation and inactiva-oligonucleotides prevented the increase in 36 Cl efflux in response to milrinone and isoproterenol. These results tion of CFTR and suggest the nature or the exact consequences of nucleotide binding differ for the two domains again demonstrate that some DF508 CFTR is functionally expressed in the plasma membrane and that it can be (428), observations that have since been demonstrated in numerous patch-clamp studies.
activated by milrinone and isoproterenol. Kelly et al. (199) have since shown the efficacy of forskolin and milrinone An important outcome of the above studies in oocytes was the demonstration that mutant forms of CFTR to hyperpolarize the nasal epithelium indicative of a Cl 0 secretory response in DF508 CFTR-expressing mice. could indeed be activated and function as Cl 0 channels. These results thus lent great support to the suggestion by Whereas the combination of forskolin and milrinone was ineffective in altering the nasal potential difference in the McPherson et al. (251) that alkylxanthines could be useful in the treatment of CF. This notion received further sup-CFTR (0/0) mice, the DF508 CFTR-expressing mice displayed a change in potential difference of Ç50% of that port from the studies of Yang et al. (440), who extended the observations in oocytes to murine fibroblast cells (L observed in mice expressing at least one wild-type CFTR allele. As in the in vitro studies with DF508 CFTR-expresscells) expressing mutant forms of CFTR. With the use of the halide-sensitive fluorophore SPQ assay, 4 mM IBMX ing cells, both an adenylyl cyclase agonist and milrinone were required to cause a response in vivo. was found to activate DF508 and G551D CFTR-mediated anion efflux. Activation by IBMX of the DF508 CFTR exCollectively, these studies on human salivary acinar cells, Xenopus oocytes, human airway cells, murine fipressing cells was observed in cells maintained at 37ЊC, indicating some DF508 CFTR protein had reached the broblasts, and murine nasal epithelia suggest the superactivation of the cAMP-PKA regulatory pathway may actiplasma membrane. Similar stimulatory effects of IBMX were also reported by Haws et al. (159) using mouse mam-vate certain mutant forms of CFTR and thus be of thera-S121 peutic utility in the treatment of CF. However, there are antibody that detected and reduced apical membrane alkaline phosphatase activated quiescent CFTR Cl 0 chana few caveats that bear consideration. In addition to IBMX inhibition of PDE, one must also consider the inhibition nels. Subsequently, Becq et al. (30) showed in CFTR expressing Chinese hamster ovary (CHO) and human airway of phosphatases as a possible site of action as demonstrated by Becq and co-workers (29, 30) (see below). If epithelial cells that the alkaline phosphatase inhibitors bromotetramisole, IBMX, theophylline, and vanadate (Fig. phosphatase inhibition or a combination of phosphatase inhibition and PDE inhibition is the mechanism, then one 3; each at 1 mM) slowed the rundown of CFTR channel activity in excised membrane patches. These same submust modify the interpretation of these results, and consequently, a different strategy will be required to optimize stances also reduced the dephosphorylation of CFTR protein in isolated membranes. 3-Isobutyl-1-methylxanthine this therapeutic approach. The studies with milrinone were performed at a single high concentration of 100 mM. was the most effective at slowing channel rundown. Caffeine (Fig. 3) and dipyridamole, two PDE inhibitors that The K i of milrinone is 0.3 mM for inhibition of class III PDE (28). Milrinone concentration-response studies as well as only poorly inhibit phosphatases, were ineffective in slowing rundown as was okadaic acid (10 mM), a type 1 and the biochemical demonstration of the presence of class III PDE in the apical membrane of airway epithelial cells 2A protein phosphatase inhibitor. (0)-p-Bromotetramisole and IBMX also activated wild-type and the diseaseare needed before one can conclude the stimulatory effects of milrinone are mediated by inhibition of class III causing mutant CFTR, R117H, G551D, and DF508 in cellattached patches. We have also observed that IBMX slows PDE. In addition, the assumed activation of the cAMP-PKA regulatory pathway by IBMX or milrinone is ex-the rundown of DF508-CFTR in excised membrane patches from L cells (322, 326). These results in excised pected to lead to the phosphorylation of the mutant CFTR proteins. Protein phosphorylation studies are needed to membrane patches and isolated membrane vesicles cannot be explained by the inhibition of PDE but rather sugdemonstrate that IBMX and milrinone do alter the phosphorylation status of CFTR under the experimental condi-gest the inhibition of membrane-associated phosphatases, perhaps alkaline phosphatase, as the site and mechanism tions used in these studies. Positive results from such biochemical studies would lend great support to the con-of action. However, on a cautionary note, one must consider the concentrations of the substances used in these clusions reached by these investigators. These studies must also be reconciled with the observations of Grubb studies. (30) evaluated these compounds at 1 mM and suggest IBMX was the more potent compound at slowing Neither forskolin nor forskolin plus IBMX had any effect in cells from CF patients with the DF508 mutation even CFTR channel rundown. Therefore, concentration-response studies that show a EC 50 on CFTR channel activity in the presence of a favorable Cl 0 gradient. Nasal potential difference measurements failed to detect an additive ef-consistent with the K i for alkaline phosphatase inhibition would aid in delineating the site and mechanism of action fect of IBMX with isoproterenol in either normal or CF subjects. Grubb et al. (148) concluded that the combina-of these substances.
The direct binding of the alkylxanthines to CFTR also tion of adenylyl cyclase activators and IBMX is not effective in initiating Cl 0 secretion in CF epithelia. These au-warrants some consideration when attempting to understand their mechanism of action on CFTR channel gating. thors also note that agents that raise cell cAMP in CF airways may further increase the abnormally high basal We and others (322, 428) have observed that IBMX causes a decrease in the single-channel amplitude of CFTR and rate of sodium absorption. Thus Cl 0 secretagogues that elevate cAMP levels may be counterproductive in the thus appears to act as an open-channel blocker. Thus IBMX will by mass action hold CFTR in the open (albeit partially treatment of CF airways (148) .
The studies of Becq et al. (29) suggest an alternative blocked) state. If only closed CFTR channels can be dephosphorylated, IBMX, by stabilizing the open state, will slow explanation for the effects of high concentrations of IBMX. These investigators observed that channel inactiva-dephosphorylation and channel inactivation (rundown). In support of this hypothesis, we have observed that lowering tion (rundown) that is often observed upon patch excision could be slowed by theophylline, IBMX, and levamisole the bath ATP concentration in excised inside-out patches, a manipulation that lowers the P o , also accelerates wild- (Fig. 3) in wild-type CFTR-expressing CF pancreatic cell line CFPAC-PLJ-CFTR-6. These same substances reduced type CFTR rundown. The DF508 CFTR has a lower affinity for ATP (K S 300 mM vs. wild-type CFTR 25 mM), a lower the apical membrane-associated alkaline phosphatase activity by 70-75%. A polyclonal antialkaline phosphatase maximal P o (0.25 vs. wild-type CFTR 0.4), and tends to S122 rundown more rapidly than wild-type CFTR. 3-Isobutyl-1-significant modulatory roles. In the following paragraphs, we discuss the pharmaceutical compounds that have been methylxanthine tends to slow the rundown of DF508 CFTR. The effects of IBMX on wild-type and mutant CFTR may used to infer phosphatase-dependent modulation of CFTR Cl 0 channel activity and the associated supporting obsertherefore in part be mediated by a direct interaction with the CFTR protein. Clearly, further studies are needed to vations. Although it is parsimonious to conclude that channel activation associated with exposure to kinases determine the contributions of PDE inhibition, phosphatase inhibition, and direct binding to CFTR by the alkylxanthines results from channel phosphorylation, and that channel inactivation associated with exposure to phosphatases is on CFTR channel activity.
Another series of alkylxanthines that has received indicative of dephosphorylation, a healthy skepticism that awaits verification in the form of unique phosphopeptide attention by CF investigators is the potent adenosine receptor antagonists. In a series of papers by Pollard and maps associated with distinct gating modes is appropriate.
The classification of protein phosphatases can be co-workers (112, 151, 192) , compounds such as 8-cyclopentyl-1,3-dipropylxanthine (CPX; Fig. 3 ) and the xanthine quite confusing. In the most widely accepted nomenclature scheme, phosphatases are classified based on subamino congener (XAC) were reported to increase 36 Cl efflux from the DF508 CFTR-expressing CFPAC pancreatic strate specificity and inhibition by particular proteins, inhibitor 1 and inhibitor 2 (186, 187). Type 1 phosphatases cells. The response to CPX and XAC was biphasic, with low concentrations (10-30 nM) causing stimulation and (PP1) preferentially dephosphorylate the b-subunit of phosphorylase kinase and are sensitive to both inhibitory higher concentration (100 nM to 10 mM) causing inhibition of 36 Cl efflux. CFPAC cells transfected with wild-type proteins, whereas type 2 phosphatases (PP2) dephosphorylate the a-subunit and are sensitive to neither inhibitor. CFTR were not responsive to CPX or XAC. The stimulatory effects of CPX and XAC were blocked by exogenous Type 2 phosphatases have been subdivided based on requirements for divalent cations; PP2A requires no divalent adenosine agonists such as 2-chloroadenosine and were not observed in the presence of adenosine deaminase. cations, PP2B (also known as calcineurin) are regulated by Ca 2/ and calmodulin, and PP2C require Mg 2/ . In this These studies were subsequently repeated with similar results using NIH 3T3 cells expressing DF508 CFTR or nomenclature system, tyrosine phosphatases (PTP) are classified separately, whereas neither acid nor alkaline wild-type CFTR as well as with the human airway cell line IB3-1 derived from a DF508/W1282X CF patient (151) . phosphatases are represented as a unique class. Alternative classification schemes have been presented but are In a companion paper, structure-activity studies were performed using the CFPAC cells. The results demonstrated not yet widely used (263). For more complete discussion of phosphatase nomenclature and forms, the reader is there was no correlation between the potency on 36 Cl efflux and adenosine receptor antagonism (192) . Human directed to various recent reviews (20, 119, 263, 345, 425).
The discovery of okadaic acid and similarly bioactive A 1 adenosine receptor mRNA was not detected in CFPAC cells, excluding this receptor as a mediator of CPX-elicited compounds has greatly enhanced our knowledge of the role of phosphatases in physiological systems because of 36 Cl efflux. The authors suggest the action of CPX on DF508-CFPAC cells represents a novel site of action ap-their selectivity for PP1 and PP2A and their unique rank order of potency for each class. In this regard, the pharmaparently unrelated to known adenosine receptors. However, Haws et al. (159) did not observe a stimulatory effect cology of serine/threonine phosphatases PP1 and PP2A is the best developed. Alternatively, PP2B is selectively of CPX at low or high concentrations when using stably transfected mouse mammary epithelial cells (C127 cells) inhibited by FK506 and cyclosporin after their interactions with binding proteins FKBP12 and cyclophilin, respecexpressing DF508 or wild-type CFTR. At high concentrations (EC 50 58 mM), CPX did potentiate the response to tively. Distinct, unique pharmacological profiles for PP2C
and PTP based on the actions of high-affinity blockers forskolin in DF508 CFTR-expressing cells. Thus further studies will be required to establish the generality of CPX are not yet available, although the molecular forms and catalytic mechanisms have been reviewed (20, 119). efficacy on CF cells as well as its mechanism of action.
It was recognized early on that specific kinases were capable of activating CFTR; however, the phosphatases B. Phosphatase Inhibitors capable of, or responsible for, inactivation remained unknown. Tabcharani et al. (380) first showed that exogenously applied alkaline phosphatase could reduce the P o Cystic fibrosis transmembrane conductance regulator Cl 0 channel activity is thought to be reciprocally regu-of channels in membrane patches excised from CFTRexpressing CHO cells. Furthermore, the authors (380) lated by kinase-dependent phosphorylation and phosphatase-dependent dephosphorylation. Functional studies in-showed that both F 0 and metavanadate, two nonspecific phosphatase inhibitors, increased channel P o in this prepdicate that Cl 0 channels are primarily activated by PKA in physiological settings, although phosphorylation by other aration and inhibited the effects of exogenously applied alkaline phosphatase. Thus it was concluded that memkinases (e.g., protein kinase C, protein kinase G) may play brane-associated alkaline phosphatase might have been cords from guinea pig ventricular myocytes and that calyculin A (20 nM) enhanced forskolin-stimulated CFTR responsible for the inactivation of channels (rundown) that consistently accompanied patch excision. In contrast, channel activity in cell-attached patches on Hi-5 insect cells. Likewise, okadaic acid (10 nM) prevented the inactiBerger et al. (36) reported that alkaline phosphatase failed to inactivate CFTR channels in membrane patches ex-vation of forskolin-stimulated current across permeablized human sweat duct (297) , and calyculin A (EC 50 Ç0.1 cised from NIH 3T3 cells. Rather, exposure to alkaline phosphatase caused a reduction in P o that reversed upon mM) stimulated 125 I efflux from CFTR-transfected NIH 3T3 cells (298) . Taken together, these observations suggest washout and without the addition of kinases. These results were interpreted to indicate that dephosphorylation, that, in intact cells, the inhibition of either PP1, PP2A, or both results in the stabilization of an activated form of which is expected to require kinases for reversal, had not occurred but that the phosphatase had reduced the ATP CFTR. Such phosphatase inhibition could account for the apparent stimulation of CFTR activity if, in basal condiconcentration and thus caused a transient reduction in P o . Alternatively, it was shown that exogenously added tions, some ongoing kinase and phosphatase activities are present. Upon excision, elements responsive to these PP2A, but not PP1 or PP2B, was capable of reducing P o in excised membrane patches (36) . Although results from pharmaceutical compounds diffuse away from the channel and regulation attributable to PP1 or PP2A is no longer these studies demonstrate that CFTR channels expressed in these cell lines (CHO and NIH 3T3) can be inactivated evident. Whether the phosphorylation state of CFTR is, in fact, directly affected by the protein targets of these by exposure to specific phosphatases (alkaline phosphatase or PP2A, respectively), the results do not indicate compounds cannot be determined based on these results.
An intriguing and unexplained observation in these studthat these phosphatases regulate CFTR activity in vivo and especially in cells or tissues that normally express ies was that okadaic acid increased the phosphorylation of CFTR as assessed by 32 P incorporation but had no CFTR. In this vein, Travis et al. (390) reported that PP2Ca was present in colonic and airway epithelial cells, was apparent effect on CFTR channel activity as assessed by 125 I efflux (298) or channel rundown (30) . The residues capable of dephosphorylating CFTR in vitro, reduced transepithelial Cl 0 currents when over expressed, and in-that were differentially phosphorylated in the presence of okadaic acid did not apparently impinge on channel activated CFTR in excised membrane patches. These data would argue that PP2Ca might have a physiological role activity.
Protein phosphatase 2B and PP2C were first defined in CFTR regulation.
Numerous pharmacological studies designed to de-by dependence on Ca 2/ and Mg 2/ , respectively. Additionally, orthovanadate selectively inhibits PP2C, whereas F 0 termine the factors that physiologically mediate inactivation of CFTR have been completed. Compounds such as and phenothiazines selectively inhibit PP2B (345). More recently, FK506 and cyclosporin have been shown to be okadaic acid, calyculin A, and microcystin, which are known to inhibit PP1 and PP2A, have been widely used high-affinity inhibitors of PP2B. The authors are unaware of any studies designed to determine if either FK506 or to rule out or impute a potential role for these protein phosphatases in the regulation of CFTR. Historically, the cyclosporin directly affected CFTR channel gating, although Travis et al. (390) reported that FK506 did not in-''rundown'' of channel activity that accompanied patch excision and that could be reversed by addition of PKA hibit cAMP-stimulated Cl 0 currents in airway or T84 colonic epithelial cell monolayers. The removal of divalent was interpreted as dephosphorylation/inactivation (77, 380). Tabcharani et al. (380) reported that okadaic acid cations in general, and Mg 2/ in particular, has been reported to alter CFTR gating in excised membrane patches. (10 mM) did not preclude rundown of channel activity upon patch excision from CFTR-expressing CHO cells. Little effect of Ca 2/ removal was noted, indicating that PP2B did not modulate gating in excised membrane This observation led to the conclusion that protein phosphatases other than PP1 or PP2A inactivate CFTR upon patches (323, 380) . Removal of Mg 2/ has been associated with significant reductions in the nucleotide-dependent patch excision, a conclusion supported by Becq and coworkers (29, 30) from recordings of both cell-attached and opening rate of CFTR and in its closing rate (10, 63, 153, 323) . Depending on the relative effects on the opening and excised membrane patches. Similarly, neither the kinasedependent activation kinetics of CFTR channels in mem-closing rates, P o of CFTR channels was reported to either remain relatively unchanged (153, 323) or to be dramatibrane patches excised from NIH 3T3 cells expressing CFTR nor the steady-state P o of the channels was affected cally decreased (10, 63). However, results from these studies along with those from studies employing orthovanadate by the presence of either calyculin A (100 nM) or okadaic acid (1 mM; Refs. 10, 125), again indicating that PP1 and as a panspecific phosphatase inhibitor (see below) cannot be interpreted in isolation from possible effects caused by PP2A were not active in these cell-free experiments. Alternatively, Hwang and co-workers (177, 439) have reported changes in the rates of nucleotide binding and unbinding and perhaps hydrolytic events that are thought to occur at that okadaic acid (10 mM) and microcystin (5 mM) enhanced the forskolin-stimulated current in whole cell re-one or both of the NBF (27, 129, 152, 323).
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Orthovanadate has been employed in some studies pendent effects were reported, the results cannot be attributed to phosphatase inhibition with any reasonto assess the role of protein phosphatases in the regulation of CFTR (10, 30, 182, 297, 380) . Other studies have able degree of certainty.
Becq and co-workers (29 -31) have reported that employed the same compound as a hydrolytic transition state analog to investigate energy requirements for chan-the antihelminthic phenylimidazothiazole drugs (0)-pbromotetramisole and levamisole stimulated CFTR nel gating (27, 152, 323). At concentrations õ1 mM (concentrations appropriate for the inhibition of P-type channel activity in CHO cells. The stereoisomer (0)-pbromotetramisole was without effect. Likewise, Illek ATPases and PTP and known to inhibit PP1, PP2A, and PP2C), vanadate had little or no observable effect on et al. (183) have shown that (0)-p-bromotetramisole stimulated short-circuit current across Calu-3 cell CFTR channel activity in excised membrane patches (10, 323, 380) or in permeabilized human sweat duct (297) . monolayers. The authors interpreted these observations, along with those of Tabcharani et al. (380) , to When used at 1-10 mM, vanadate significantly increases the P o of CFTR in excised membrane patches (27, 30, indicate that alkaline phosphatase inactivates CFTR and that the inhibition of a tonically active alkaline 152, 323). Because of the concentrations required to elicit changes in CFTR channel activity, it is difficult to draw phosphatase accounted for stimulation. The observed stereospecific inhibition is consistent with this interany conclusions regarding the site or mechanism of action. Clearly, the concentration dependence is not consis-pretation, although the concentration dependence is not (200 mM to 2 mM; levamisole EC 50 Å 450 mM). Mettent with the inhibition of previously described protein phosphatases.
aye et al. (254) first reported the stereospecific inhibition of alkaline phosphatase by phenylimidazothiaPerhaps the most relevant and interpretable use of vanadate in the modulation of CFTR is that it inhibits genistein-zoles, but reported a K i of 1.2 mM for (0)-p-bromotetramisole and 11 mM for levamisol, two to three orders stimulated 125 I efflux and channel activity in excised and whole cell membrane patches (182, 352). In each case, sig-of magnitude lower than the concentrations used in the studies on CFTR. Furthermore, the authors (254) nificant inhibition was reported with concentrations õ100 mM. These observations are consistent with the hypothesis reported that, at concentrations approaching 1 mM, these compounds inhibited adenylyl cyclase, although that a tonically active tyrosine kinase maintains CFTR in an inactive state. Inhibition of this kinase by genistein and the not stereospecifically (254) . The effects of phenylimidazothiazoles on CFTR-mediated ion transport are not concomitant activity of PTP results in the apparent activation of CFTR. Inhibition of PTP by vanadate maintains the consistent with the pharmacology at recognized sites of action, e.g., inhibition of alkaline phosphatase. inactivated phosphotyrosine form of CFTR and thus precludes an effect of genistein. This interpretation of the data Therefore, further studies are required to define the mechanistic basis for these effects. Regardless, Becq is attractive but awaits supporting observations that indicate the distinct phosphotyrosine forms of CFTR that are present et al. (30) pointed out that enhanced secretion may explain the ability of levamisole to reduce the frein the various conditions as well as a delineation of the site and mechanism of action of genistein.
quency, severity, and duration of upper respiratory tract infections in children (98, 404, 405). Fluoride affects a variety of hydrolytic enzymes including G proteins, kinases, and phosphatases. The Additional compounds including xanthines (29, 30) and genistein (183) have been reported to stimulate CFTR concentration dependence for specific enzymes ranges from low microequivalent to the milliequivalent range. by modulating phosphatase activity. These observations are addressed elsewhere in this report. Tabcharani et al. (380) showed that 10 meq F 0 blocked the effect of exogenously added alkaline phosphatase on excised membrane patches and reported that chan-C. Isoflavones and Flavones (Genistein) nel rundown was inhibited by this treatment. In our hands, F 0 activates CFTR activity in the cell-attached configuration (410) , although stably active CFTR chanGenistein is a plant-derived isoflavone for which a biological activity was first described in the 1940s and nels in excised membrane patches are unaffected by the presence of 10 meq F 0 (323, 331, 333 ). Alterna-early 1950s (35, 46, 65, 66) . Initial reports regarding genistein dealt with estrogenic effects of this class of tively, Berger et al. (36) reported that 20 meq F 0 increased CFTR P o by twofold. Five milliequivalents F 0 compounds because of the economic impact on livestock production and potential clinical applications. slightly reduced, but did not inhibit, the reduction in Cl 0 conductance that accompanies the washout of The cellular or subcellular target mediating this effect was uncertain, but thought to be the estrogen receptor cAMP from a permeabilized human sweat duct (297) . Taken together, these results are ambiguous in that (318). In the 1980s, a related flavone, quercetin, was found to inhibit PKC (149), casein kinase (78), phosphothe results were inconsistent even with the extreme concentrations that were employed. Although F 0 -de-rylase kinase (367) , and the tyrosine kinase activity as- sociated with the Rous sarcoma virus gene product in various ATP-dependent enzymes including topoisomerase II and erb-B2 (238). 1 Akiyama and co-workers (3, pp60 src (141). In each case, significant inhibition was seen at concentrations below 100 mM, making this com-4) reported that genistein is selective by at least an order of magnitude for tyrosine kinases (EGF, gag-fes, pound one of the most ''potent'' kinase inhibitors available. While developing an SAR based on quercetin, and src) over serine/threonine kinases (PKA, PKC, phosphorylase kinase), 5-nucleotidase, and phosphodiOgawara et al. (272) reported that genistein inhibited tyrosine kinase activity of the epidermal growth factor esterase. Thus it appears that the effective concentration of genistein along with the rank order of potency (EGF) receptor and src kinase with IC 50 values of 2.6 and 30 mM, respectively, while having no effect on PKA for these compounds will differentiate effects mediated by interactions with tyrosine kinases from those mediat 375 mM. Subsequent research showed that, of 28 isoflavonoids and 5 flavonoids evaluated, genistein was ated by an interaction with topoisomerase II or the serine/threonine kinases. the most potent inhibitor of EGF receptor tyrosine kinase activity (2.6 mM) and most cytotoxic to Rous sarThere is currently tremendous interest in genistein as an oncolytic or oncostatic agent (21, 121, 284, 368; coma virus-transformed cells (26 mM) (273). The reported rank order of potency for inhibition of EGF re-for review, see Ref. 253) . Most authors have attributed oncolytic activity directly or indirectly to tyrosine kinase ceptor tyrosine kinase activity for widely available flavones (f) and isoflavones (i) is as follows: genistein inhibition (143, 144, 156, 220, 288, 397, 419, 427) . Alternatively, the oncolytic effect of genistein might be mediated
Å flavone by the interaction with topoisomerase II and accompanying increase in DNA strand breakage to induce (f) ú genistin (i) Å daidzein (i) (273). The assay was completed in a cell-free system that would likely pre-apoptosis (238, 278). Additionally, genistein has been shown to bind to P 1 purinergic (adenosine) receptors clude interactions with other binding sites that could be linked to alternative and perhaps antagonistic affects. (K i Å 5 mM; Ref. 274) and to inhibit murine multidrug resistance-associated protein (MRP) transport (K i Å 23 However, because cell membranes and/or vesicles were involved, the rank order of potency might have been mM; Ref. 282) . It should be emphasized that, when used at concentrations in excess of 100 mM, genistein has also influenced by lipid shielding of the binding site. Consistent with the rank order of potency is the observation been shown to inhibit PKC and PKA (4) and to alter cellular metabolism by inhibiting b-galactosidase (162) . that genistein is more hydrophobic than daidzein (22) or genistin. It is also intriguing to note that there seems In summary, genistein is the most potent of many flavones and isoflavones that have been reported to inhibit to be little selectivity between flavones and isoflavones at the active site. This could, in part, be because of the protein tyrosine kinases, topoisomerase, and certain other ATP-requiring enzymes. In the case of tyrosine kinase, freedom of rotation for the phenyl group attached to the chroman ring system at C 2 or C 3 of isoflavones and inhibition is competitive with ATP. Inhibition of these enzymatic activities or interaction with yet undetermined flavones, respectively ( Fig. 3; Ref. 22 ). Certain hydroxyl substituents on the chroman ring appear to be quite binding sites causes estrogenic, antiestrogenic, oncolytic, angiostatic, and apoptotic events along with the plethora important for activity. An hydroxyl at C 3 of flavones provides for greater kinase inhibition (kaempferol or of other cellular processes that are reportedly affected by genistein. If genistein is to be of therapeutic value in the quercetin vs. apigenin), and a substituent at C 5 appears to be required for activity (daidzein or flavone vs. gen-treatment of CF, then these activities of genistein will have to be considered in concert with the targeted cell istein). Kinetic analysis indicated that the inhibition of EGF receptor tyrosine kinase activity by genistein is processes.
That genistein and some related flavones and isoflacompetitive with ATP (K i Ç13.7 mM) but is noncompetitive or mixed inhibition with the phosphate acceptor vones affect epithelial ion transport is now widely accepted. Such effects of flavones on CFTR-mediated ion (3, 4) . A more limited pharmacological profile showed that, of six flavones and isoflavones evaluated, genistein transport were first reported by Nguyen et al. (264), who showed that quercetin and kaempferol stimulated Cl 0 sewas singular in its potency as an inducer of DNA strand breakage due to its interaction with topoisomerase II cretion across T84 cell monolayers. The authors speculated that because quercetin-induced stimulation was po-(effective concentration 5 mM) (238, 278). Genistin was 10-fold less effective, whereas prunetin, quercetin, api-tentiated by carbachol, but not VIP, and because quercetin produced a phosphoprotein map like that observed in the genin, and biochanin A were without effect at 100 mM. Although assays were not performed to definitively de-presence of cAMP (increased phosphorylation of proteins termine the site of action, the ATPase activity of topo-S126 designated p18, p23, and p37), the effects were likely me-recently, Diener and Hug (97) reported similar observations in rat colon. None of the authors (97, 182, 338) prodiated by a PKA-dependent mechanism. An effect of quercetin on adenylyl cyclase activity was ruled out by the vided evidence for a direct effect of genistein on CFTR.
However, Sears et al. (338) showed that genistein potentiobservation that cAMP production was unchanged. In more recent and extensive reports, the mechanisms by ated, by fourfold, the effect of forskolin (10 mM) on intracellular cAMP production in T84 cell monolayers, sugwhich stimulation of CFTR occurs have been contested. As in the following paragraphs, valid arguments have been gesting that the target for genistein might be a part of this second messenger pathway subsequent to the activation made that genistein affects CFTR-mediated ion transport by direct interaction with the channel, by inhibition of of adenylyl cyclase. Lehrich and Forrest (221) reported that genistein, but not genistin, stimulated bumetanideprotein phosphatases, and by inhibition of tyrosine kinases. Perhaps what has added the greatest fuel to the inhibitable Cl 0 secretion in shark rectal glands with an EC 50 õ50 mM when applied to the apical membrane. The debate is the variety of settings in which genistein is being applied to CFTR and the lack of extensive pharmacologi-tissue was less sensitive to basolateral genistein application. Genistein consistently reduced the labeling of four cal profiles in any one of these settings. Since the start of 1995, no less than 15 reports have appeared which address proteins (240, 210, 55, and 53 kDa) by a monoclonal antibody (4G10) raised against phosphotyrosine residues, rethe effects of genistein on CFTR. Numerous wild-type and mutant forms of CFTR have been evaluated in Xenopus portedly indicating the inhibition of a tyrosine kinase.
However, the inhibition of protein phosphorylation was oocytes, insect cells, fibroblasts, epithelial cell lines, cardiac cells, and shark rectal gland cells. Measurements seen only at concentrations far in excess of those required to stimulate ion transport (¢250 mM vs. õ50 mM) and, in have been made to determine the effects of genistein on Cl 0 secretion, short-circuit current, 125 I efflux, intracellu-fact, labeling of each of these proteins was increased in the presence of 100 mM genistein. Alternatively, Bischof lar cAMP concentrations, protein phosphorylation levels, and the activity of CFTR in whole cell, cell-attached, and et al. (40) reported that, in HT-29 cells, 50 mM genistein prevented carbachol-induced phosphorylation of three excised membrane patches. On top of this diversity in constructs, assays, and expression systems is superim-proteins (110, 75, and 70 kDa) and inhibited carbacholinduced Ca 2/ entry. Similar effects were seen with other posed the conditions for evaluation which include differences in temperature, ionic environment, pH, and mem-known tyrosine kinase inhibitors (methyl-2,5-dihydroxycinnamate, lavendustin A), but not daidzein. Finally, obbrane potential. It is no wonder that not all systems have given consistent and thus easily interpretable answers. servations by Shuba et al. (352) regarding genistein-stimulated Cl 0 currents in whole cell records of guinea pig However, some generalizations are possible at this time.
The first question that must be addressed is, Is the cardiac myocytes suggest the participation of a tyrosine kinase in this system; the stimulation was vanadate sensieffect of genistein on CFTR mediated by a tyrosine kinase? At best, the answer is that there may be a tyrosine tive, and daidzein was virtually without effect. It should be noted that these authors report an EC 50 of 100 mM, kinase component in some systems. Undoubtedly, results first reported by Illek et al. (182) from experiments em-significantly greater than the K i for tyrosine kinase inhibition reported in other systems. The observations thus far ploying CFTR-expressing NIH 3T3 cells are consistent with this hypothesis. In both 125 I efflux and cell-attached cited are consistent with tyrosine kinase involvement; however, many questions remain unanswered. Perhaps membrane patches, the concentration of genistein employed (40-50 mM) is appropriate for the selective inhibi-most important, in all systems tested, CFTR was not isolated either physiologically or biochemically to determine tion of tyrosine kinases; daidzein, an analog known not to affect EGF receptor tyrosine kinase, was without ef-if there was a genistein-dependent change in CFTR phosphorylation or if there was reason to impute a direct effect fect, and a known tyrosine phosphatase inhibitor, vanadate, inhibited the response. The authors reported that of genistein on channel biophysics. Subsequent reports have dealt with these issues. tyrphostin B42, a structurally unrelated tyrosine kinase inhibitor, had similar effects to those of genistein. Like the Hwang et al. (178) reported that, in membrane patches excised from NIH 3T3 cells containing previously earlier report by Nguyen et al. (264) and as an additional control, it was reported that alternative second messenger activated CFTR channels, genistein did not support channel gating. This observation rules out a simple bimolecular concentrations (cAMP, Ca http://physrev.physiology.org/ Downloaded from S127 tase activities, genistein could, by inhibiting a phospha-ratio of phosphorylated to dephosphorylated channels. As other authors have noted, the P o of DF508 CFTR was tase, increase the functional activity of CFTR. Alternatively, in cells that are strongly stimulated (i.e., PKA activ-reported to be less than that of wild-type CFTR in similar conditions (85, 159, 322). The reduced P o could reflect ity significantly greater than phosphatase activity), varying degrees of additional activation by genistein are changes in the cell's ability to phosphorylate the protein, changes in the stability of the phosphorylated state (i.e., observed. At the level of the tissue or in intact cells, this is supported by observations that genistein will increase the rate of dephosphorylation), or changes in the rates of nucleotide-dependent channel opening and closing. epithelial ion transport during submaximal cAMP-dependent stimulation, but not during maximal stimulation, and Hwang et al. (178) report that the activation rate of DF508
CFTR is significantly reduced compared with wild-type that secretion is prolonged after cAMP removal (97, 181). Further support of this concept comes from the observa-CFTR, while we have proposed that the dephosphorylation/inactivation rate of DF508 CFTR is greater than that tion that CFTR is similarly phosphorylated in the presence of either forskolin or genistein (298) . This model for the of wild-type CFTR (322, 333). Regardless, once activated, genistein can directly interact with DF508 CFTR channels predominant effect of genistein has significant clinical ramifications if mutant forms of CFTR including DF508 to prolong the phosphorylated, actively gating state of the channel. This concept is consistent with most observa-CFTR are less likely to be activated by phosphorylation (178) or if inactivation is more rapid (322). Indeed, we tions reported to date.
It is tenuous to assess kinetic parameters for activahave now reported that genistein potentiates the effect of maximally effective concentrations of IBMX (5 mM) and tion and inactivation processes involving enzymatically catalyzed reactions at room temperature if extrapolations forskolin (10 mM) on G551D CFTR-expressing oocytes, whereas there is no effect on unstimulated or maximally to physiologically relevant conditions are intended. This is important to note since the only kinetic data currently stimulated oocytes expressing wild-type CFTR (327) . Although the inhibition of a protein phosphatase by gen-available are derived from experiments completed at ambient temperature (178, 439) . Because each enzyme in istein can explain these observations, there have been no studies demonstrating that genistein does inhibit any of the activation and inactivation cascade and the kinetic behavior of CFTR itself likely exhibits a unique Q 10 , the the known phosphatases, and the specific phosphatases that regulate CFTR inactivation remain to be elucidated. distribution of kinetic states available for modulation by genistein will be different at each temperature. FurtherThe observation that genistein does not support channel gating in the absence of phosphorylation and/or nucle-more, different cell types (Hi-5 insect cells, NIH 3T3, L cells, Xenopus oocytes) would be expected to provide otides does not rule out the possibility for direct interaction with some unique phosphorylated or kinetic state forms of regulatory proteins that are designed to function at the appropriate temperature for that cell type. For exof the channel. Hwang and co-workers (178, 439) have reported direct effects of genistein on CFTR channel gat-ample, Bijman et al. (39) reported that the nucleotide dependence of CFTR channel gating changes with temperaing both in the cell-attached and excised membrane patch configurations. Both variance analysis and fluctuation ture, and we have shown that cooling excised membrane patches of L cells in the presence of PKA and ATP results analysis indicated that genistein altered the gating behavior of forskolin-stimulated CFTR in cell-attached mem-in reduced CFTR channel amplitude and prolonged openings of the channels, a kinetic state that was not observed brane patches. Results from cell-attached membrane patches were interpreted to indicate that genistein pro-at 37ЊC (333) . Additionally, it is important to recall that genistein may interact with multiple binding sites that longed the burst duration of CFTR and thus increased P o . However, the 2-or 3-fold increase in P o was not sufficient might affect ion transport in any given cell type (see Fig.  1 ). In fact, genistein has been reported to reduce transepito account for the genistein-induced 45-fold increase in macroscopic current reported by the authors. Similar gen-thelial Cl 0 movement by inhibiting the function of a basolateral K / channel (97, 181) and might have effects via istein-induced changes in P o of CFTR channels were observed in excised membrane patches for Xenopus oocytes interactions with purinergic receptors (194, 274) .
Although it is often quoted that genistein is a specific and NIH 3T3 cells (124, 421) . In each case, the authors concluded that genistein directly interacts with CFTR to tyrosine kinase inhibitor (3, 272) , it is almost certain that the effects of genistein on CFTR are not modulated excluincrease P o and discount any role for genistein in the modulation of protein kinases or phosphatases. Specula-sively or even predominantly by an interaction with tyrosine kinase. It is, however, intriguing that some tyrphostion is provided regarding the domain that might be affected, a nucleotide binding domain, although no data are tins and chemically unrelated tyrosine kinase inhibitors have been reported to affect CFTR-mediated ion transport provided to support the claims (124, 421) .
Hwang et al. (178) have alluded to a more unifying (124, 182, 338) . With the consideration of the diversity of systems evaluated, it is not remarkable to observe complemodel for the effect of genistein on DF508 CFTR in which a direct interaction of genistein with the channel alters the mentary effects of some tyrosine kinase inhibitors on P21-8 / 9j0e$$ja07 01-13-99 15:10:08 prsa APS-Phys Rev 
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some occasions. Alternatively, it has been reported that by inducing a parallel shift in the voltage dependence of BK activation in whole cell recordings. These studies were erbstatin analog, tyrphostins A23, A51, and AG126, cantharidin, and herbimycin, all inhibitors of tyrosine kinase, subsequently extended by demonstrating that the structurally related analog NS004 induced a parallel shift in the did not mimic the effects of genistein on ion transport (76, 124, 181) . This broader pharmacological perspective P o versus membrane voltage relationship for single BK channels studied in lipid bilayers (246) . In both of these is not consistent with previously defined tyrosine kinases (68). Recent work in our laboratory has shown that both studies, single-channel recording techniques demonstrated that the benzimidazolones directly increased the flavones and isoflavones modulate the activity of CFTR expressed in Xenopus oocytes and in T84 cell monolayers. P o of BK channels and that this increase in P o was due to both an increase in channel open time as well as a deMost importantly, we have noted a rank order of potency (genistein ú apigenin ú daidzein ú flavone) that is pre-crease in channel closed time (246, 276) .
To define the mechanism by which these benzimidaserved between these diverse systems (unpublished observations) and separates the effects of flavones and zolones activate BK channels, the Ca 2/ dependence of activation was investigated. Both Olesen et al. (276) and isoflavones on CFTR-mediated ion transport from previously reported pharmacological profiles on PTP and to-Holland et al. (168) demonstrated that NS1619 failed to activate BK channels in the absence of added bath Ca 2/ in poisomerases. Thus, although questions remain regarding the location of the genistein binding site(s), the physico-excised patch-clamp recordings. These results suggested that the observed activation was due to a shift in the chemical constraints of the binding site(s), and the mechanism(s) by which genistein modifies mutant CFTR chan-Ca 2/ affinity of the channel rather than NS1619 simply substituting for Ca 2/ in activating the channel. However, nel activity, it is undeniable that genistein holds great promise as a prototype therapeutic agent and research both Hu and Kim (172) and McKay et al. (246) found that NS004 continued to activate BK channels in the nominal tool. The utility of this compound is underscored by recent reports in which the stimulatory effect of genistein absence of bath Ca 2/ in excised patches. Similarly, Vandier and Bonnet (402) and Edwards et al. (109) found that on ion transport is interpreted as evidence that CFTR is present (183, 386) .
NS004 and NS1619, respectively, activated BK channels in the absence of Ca 2/ . However, the experiments of Vandier and Bonnet (402) and Edwards et al. (109) were done D. Benzimidazolones in the whole cell recording mode where Ca 2/ at the plasma membrane may have been somewhat elevated. The disparate results in the excised patch configuration may be due The benzimidazoles were first characterized as novel openers of large-conductance Ca 2/ -dependent K / (BK, to structural differences between the benzimidazolones NS004 and NS1619 or may represent differences between maxi K) channels in a European patent application (EPA 0477819A2) filed by NeuroSearch A/S. Olesen et al. (276) tissues. An additional possibility is that the regulatory status of the channel may determine the effect of the demonstrated that the most potent of these compounds, NS1619 [1-(2-hydroxy-5-trifluoromethylphenyl)-5-triflu-benzimidazolone. For example, the phosphorylation state of the channel may be an important determinant of benoromethyl-2(3H)benzimidazolone; Fig. 3 ] activated BK channels from bovine aortic smooth muscle cells in a zimidazolone effects. Additional experimentation will be required to fully appreciate the mechanism by which the concentration-dependent (3-30 mM) manner. In contrast, NS1619 had no reported effect on a wide range of addi-benzimidazolones activate BK channels.
It is now known that both voltage-activated (K v ) and tional ion channels or seven membrane-spanning domain receptors (276) . Thus this class of compounds repre-maxi K channels consist of a pore-forming a-subunit coupled with a regulatory b-subunit (207, 235, 299, 337, 393) . sented the first known pharmacological openers of this important class of K / channels. Both NS1619 and its struc-Although the K v b-subunit is a cytoplasmic protein (235, 299, 337), the b-subunit associated with the maxi K chanturally related analogs, NS004 [5-trifluoromethyl-(5-chloro-2-hydroxyphenyl)-1,3-dihydro-2H-benzimidazole-2-nel consists of two membrane-spanning domains and a large extracellular loop (207) . The K v b-subunit has been one; Fig. 3 ] and NS1608 [N-(3-(trifluoromethyl) phenyl)-N-(2-hydroxy-5-chlorophenyl)urea] have now been shown to shown to interact with the NH 2 -terminal end of the K v asubunit (435), thereby inducing inactivation of the K / curactivate BK channels in a wide range of tissues including smooth muscle from guinea pig and human urinary blad-rent (165, 299, 435) . Similarly, the expression of both aand b-subunits of the maxi K channel has been shown to der (172, 392) , rat cerebral artery (168) , porcine pulmonary artery (402) , porcine (173) and canine (436) coronary shift both the voltage dependence and Ca 2/ dependence of activation (107, 247, 393) . This effect of the b-subunit artery, neurons from the ventromedial hypothalamus (339) , GH 3 cells (246) , and Xenopus oocytes expressing is similar to the effect described for NS004 (246, 276 http://physrev.physiology.org/ Downloaded from S129 studies employing coexpression of the a-and b-subunits increase in CFTR-dependent current (327) . Unfortunately, we have been unable to routinely activate either wild-type of the maxi K channel. Activation of the maxi K channel by dehydrosoyasaponin I was absolutely dependent on or G551D CFTR with NS004 in excised inside-out patches from mouse L cells recombinantly expressing CFTR (unexpression of the b-subunit (247) , whereas activation by NS1619 was independent of b-subunit expression (107). published observations). Similarly, excised inside-out patches obtained from oocytes expressing wild-type These results suggest that the benzimidazolones interact with the a-subunit of the channel.
CFTR could only be sporadically activated by NS004 (V. Gribkoff, personal communication). Lazdunski and colAlthough the benzimidazolones were initially thought to be specific activators of BK channels, more recent evi-leagues (147) did not report the effect of NS004 in excised inside-out patches. dence has demonstrated that they also inhibit K v channels in smooth muscle (109, 168), as well as voltage-dependent
The observations that NS004 and 8-methoxypsoralen (8-MOP; Fig. 3 ; see below) only sporadically activate Ca 2/ channels in vascular smooth muscle (109, 168), cerebellar granule cells (277), and isolated rat heart (319) . CFTR in excised inside-out patches while consistently activating the channel in both oocytes and intact epithelial Additionally, NS004 has been shown to inhibit both a delayed rectifier K / current and a K ATP channel in smooth monolayers suggest that either these pharmacological ''openers'' are not working directly on the CFTR protein muscle (436) . Thus it is now apparent that the benzimidazolones modulate the activity of numerous ion channels or that CFTR must be in a conformational state that is permissive for activation. Our own observations suggest and, as such, a macroscopic effect must be interpreted with caution.
that CFTR must be at least partially phosphorylated before NS004 is capable of activating the channel in Xenopus A critical breakthrough in the pharmacology of CFTR came in 1994 when Lazdunski and colleagues (147) dem-oocytes. Also, Lazdunski and co-workers (147) found that CFTR must first be activated by forskolin before NS004 onstrated that one of the benzimidazolones, NS004, activated both wild-type and DF508 CFTR in both the Xeno-is capable of activating CFTR during outside-out patchclamp recording. One possibility to explain these diverpus oocyte expression system as well as in excised outside-out patches from Vero cells transiently expressing gent results is that a cytoplasmic component necessary for the activation of CFTR by NS004 is entrapped by the the CFTR protein. More recently, these authors demonstrated, using I 0 efflux and whole cell patch-clamp mea-formation of the outside-out patch. A second possibility is that the phosporylation state of the channel obtained surements, that NS004 similarly activated an additional CFTR mutant, P574H, while failing to activate the CF-during activation by forskolin is distinct from that after activation of the channel by exogenous PKA/ATP in an causing R560T or DI507 CFTR mutants (70). Thus NS004 was the first described pharmacological opener of CFTR. excised patch, and it is this level and/or sites of phosphorylation that define the state of the channel that can be In Xenopus oocytes, NS004 activated wild-type CFTR current to Ç30-60% of that seen with elevated cAMP. In further modulated by NS004. A final possibility that must be borne in mind is that these pharmacological modulacontrast, in excised outside-out patches, no effect of NS004 was seen unless CFTR was first activated by cAMP tors of CFTR activity may be operating via an unspecified second messenger to increase channel activity. Clearly, a (147). These results suggest that NS004 cannot activate CFTR unless it is in a permissive, phosphorylated state. great deal more study is required to elucidate the mechanism of action of the CFTR openers thus far defined. Also, after maximal activation with cAMP, wild-type CFTR cannot be further activated by NS004 in Xenopus oocytes.
Although the above results demonstrate that NS004 is capable of opening both wild-type and mutant CFTR, In contrast to these results, DF508 CFTR could not be activated in the oocyte expression system unless it was these studies do not address whether NS004 will stimulate a transepithelial Cl 0 secretory response. Thus we deterfirst activated by cAMP (147).
We recently evaluated the effect of NS004 on both mined whether NS004 would stimulate transepithelial Cl 0 secretion across monolayers of the colonic cell line T84. wild-type and G551D CFTR in the Xenopus oocyte expression system (327) . In contrast to the results of Lazdunski We demonstrated that NS004 activated an apical membrane Cl 0 conductance in nystatin-permeabilized T84 and colleagues (147), we were unable to detect any activation of wild-type CFTR in the absence of first partially monolayers but failed to stimulate a transepithelial Cl 0 secretory response in intact monolayers (93). Similar reactivating CFTR with a low concentration of forskolin plus IBMX. These differences may be explained by dif-sults were obtained with NS1619 (93). Both NS004 and NS1619 also failed to stimulate a Cl 0 secretory response fering levels of basal cAMP present in our experiments and those of Lazdunski and colleagues (147). Similar to after stimulation of Cl 0 secretion by forskolin (93). In contrast to this response, the benzimidazolone 1-ethyl-2-the results on DF508 CFTR (147), we found that after activation of G551D CFTR with a maximal concentration benzimidazolinone (1-EBIO; Fig. 3 ) stimulated a sustained charybdotoxin-sensitive Cl 0 secretory response (93, 95). of forskolin (10 mM) plus IBMX (5 mM), the subsequent addition of NS004 (30 mM) induced an additional twofold Unfortunately, 1-EBIO has a low affinity for this effect S130 (EC 50 Ç500 mM). Because we previously demonstrated a basolateral membrane BK channel by NS004. -mediated agonist thereby provides the driving force required to sustain a Cl 0 secretory response in the presence of a Cl 0 channel carbachol (93). These results suggested that 1-EBIO activated K Ca , whereas NS004 and NS1619 did not. This was opener (e.g., NS004, 8-MOP). This is consistent with the observation that, after inhibition of basal Na / absorption directly confirmed in excised inside-out patches, i.e., neither NS004 nor NS1619 (10-100 mM) activated K Ca , with amiloride, Cl 0 is above electrochemical equilibrium across the apical membrane in human airway epithelia whereas the subsequent addition of 1-EBIO (100 mM) induced a 10-to 15- channel openers in the human airway. Thus one of the aims of our group is to identify novel, potent openers of secretory response in freshly excised murine trachea, after inhibition of Na / transport with amiloride. In paired basolateral membrane K / channels in the hopes of utilizing these as therapeutic tools in CF. However, we apprecitracheas, forskolin increased Cl 0 secretion by Ç40 mA/ cm 2 , and this was not further stimulated by NS004 ate the difficulty associated with moving an investigational new drug into a clinical setting. Therefore, we have (E. W. Alton, personal communication). In contrast to these results, NS004 had no effect on in vivo nasal poten-attempted to identify drugs that are currently approved by the Food and Drug Administration for the treatment tial difference measurements in the G551D mouse in the absence or presence of forskolin (Alton, personal commu-of other diseases that share structural similarity to the benzimidazolones. These drugs were then evaluated for nication).
In contrast to our results from T84 cells and primary their ability to activate the K Ca in intact monolayers and excised patches. Using this approach, we have identified cultures of MTE, we recently demonstrated that both NS004 (10 mM) and 8-MOP (10 mM) stimulate transepithe-the centrally acting muscle relaxants chlorzoxazone and zoxazolamine (Fig. 3) http://physrev.physiology.org/ Downloaded from S131 peak plasma concentrations found in vivo (see below). In gerprint of hIK1, suggest this is the basolateral membrane K Ca of colonic and airway epithelia. Based on this, we addition, both chlorzoxazone and zoxazolamine activated K Ca in excised inside-out patches (356) . We have now dem-determined the effect of the K Ca openers 1-EBIO, chlorzoxazone, and zoxazolamine on hIK1 as well as rSK2 hetonstrated, using the paradigm of Knowles et al. (208) , that chlorzoxazone induces a hyperpolarization of the transep-erologously expressed in Xenopus oocytes. Chlorzoxazone, 1-EBIO, and zoxazolamine all activate both hIK1 ithelial nasal potential difference in normal volunteers after inhibition of the basal Na / absorption with amiloride and rSK2 during both two-electrode voltage-clamp and excised inside-out patch-clamp recordings (378) . Similar and establishment of a blood-to-lumen Cl 0 concentration gradient (M. Gondor, personal communication). This hy-to what we previously reported on the endogenous K Ca in T84 cells, activation by these pharmacological agents is perpolarization is indicative of an induced Cl 0 secretory response. Thus these results demonstrate the utility of dependent on the presence of physiological levels of cytoplasmic Ca 2/ . Also, the primary metabolite of chlorzoxaaugmenting the basolateral membrane K / conductance in sustaining a Cl 0 secretory response in the human airway. zone, 6-hydroxychlorzoxazone, fails to activate either hIK1 or rSK2 (378) , similar to our results on the T84 K Ca Chlorzoxazone is approved by the Food and Drug Administration as an adjunct therapy for the relief of acute (356) . These results further suggest that the centrally acting muscle relaxant effects of these compounds are remusculoskeletal pain. At high doses (600-750 mg), a peak plasma concentration of 100-200 mM is obtained (113, lated to their ability to activate neuronal K / channels (SK), which would be predicted to hyperpolarize the neuron 369), with a half-life of Ç1 h. The concentration in kidney and muscle is approximately one-half that found in thus decreasing firing rate as observed. In future studies, it will be important to define the mechanism by which plasma. Although the benzodiazepines have largely displaced the use of these muscle relaxants, at one point these pharmacological K / channel openers modulate the Ca 2/ -dependent gating of both hIK1 and rSK2. they were included on the list of the 200 most prescribed drug products. In spite of the fact that these drugs were
The major metabolic product of chlorzoxazone is 6-hydroxychlorzoxazone (369) . The generation of this meintroduced over 40 years ago, their mechanism of action remains largely unknown, and with their limited current tabolite has been used as a means of quantifying cytochrome P-450 2E1 activity, since this has been shown use in the clinical realm research into their mechanism of action has virtually ceased. These drugs preferentially to be the major isozyme responsible for the metabolic conversion of chlorzoxazone (15, 74, 232, 437) . More resuppress polysynaptic reflexes and have been shown to decrease striatal dopamine turnover and decrease neu-cently, however, the 3A and 1B1 isozymes of cytochrome P-450 have also been shown to make a contribution to ronal firing rate (240, 248). The mechanism for this effect is unknown but does not appear to involve strychnine-the 6-hydroxylation of chlorzoxazone (137, 349) . In contrast to chlorzoxazone, we have demonstrated that 6-hyinsensitive glycine or GABA B receptors (248) . Although our recent results do not address the mechanism by which droxychlorzoxazone fails to activate K Ca in excised insideout patches (356) . Because the cytochrome P-450 have these agents affect neuronal firing, we have demonstrated a direct effect on K Ca (356) , suggesting that a direct effect been shown to exist in significant quantities in lung tissue (134, 239) , it will be important to determine whether the on an ion-conductive pathway may be important in determining their clinical efficacy. (210) , IK is expressed peripherally in epithelial tissues including lung and colon (188).
The psoralens (Fig. 3) are planar, tricyclic furocoumarins, being composed of a furan ring fused to a coumaBoth rSK2 and hIK1 have been generously given to us by Dr. J. P. Adelman (Vollum Institute, Oregon Health Sci-rin moiety. In contrast, the angelicins are angular psoralens. The psoralens are found naturally in a wide variety ences University). We have demonstrated expression of hIK1 in both the human colonic cell line T84 as well as of plants including limes, parsnip, celery, and figs as well as in certain fungi. The photochemotherapeutic potential the human airway serous cell line calu-3, employing both Northern analysis as well as indirect immunofluorescence of these compounds was first recognized Ç3.5 millennia ago by the herbalist's of ancient India and Egypt who using an antibody directed against the COOH-terminal tail of hIK1 (45; unpublished observations). These results, treated vitiligo with the extracts of plants known to contain psoralens to induce repigmentation upon exposure coupled with the biophysical and pharmacological fin-S132 to sunlight. In 1947, El-Mofty (114) began treating patients genes (396) . Similarly, Cotten and colleagues (16, 79) Parrish et al. (280) . In these studies, it was demonstrated that psoriasis could be effec-did not affect the ability of the adenovirus to enhance the cellular delivery of polylysine-ligand packaged DNA. More tively treated with a combination of psoralens and longwave ultraviolet light (PUVA). The psoralen most com-recently, Baker and Cotten (16) demonstrated that this 8-MOP-inactivated adenovirus could be used to transfer monly used for this purpose is the naturally occurring 8-MOP, although more recently 5-methoxypsoralen (Ber-bacterial artificial chromosomes of up to 170 kb into mammalian cells. Thus the use of psoralen-inactivated virus gapten) has been shown to be effective while having fewer side effects (135) . Since this initial trial, psoralen photo-particles may provide an alternative gene delivery system for CFTR. chemotherapy has been used to successfully treat more than 30 conditions including rheumatoid arthritis, cutaIn addition to its effects on DNA replication, 8-MOP has been shown to be a potent (K i Å 10-25 mM) suicide neous T-cell lymphoma, and numerous photodermatoses (169) , although the mechanism underlying its therapeutic inhibitor of cytochrome P-450 (122, 218, 223). This inhibition is due to the initial activation of 8-MOP by cytobenefit remains unknown.
The photochemical reaction of the psoralens is com-chrome P-450 into a metabolite that then covalently binds microsomal proteins and inhibits cytochrome P-450 (122). plex, involving at least two separate reactions. The first, and perhaps better known, is the mechanism by which Szewczyk et al. (379) demonstrated in 1992 that 8-MOP inhibited both the ATP-sensitive K / channel of panthe psoralens intercalate into the DNA double helix. Upon absorption of long-wave ultraviolet light, the psoralens creatic b-cells (K ATP ) as well as a delayed rectifier K / channel similarly expressed in these cells. As detailed form a monofunctional adduct with thymine and cytosine. Absorption of additional photons allows the linear pso-above, the well-known K ATP inhibitors glibenclamide and tolbutamide were also found to inhibit the CFTR Cl 0 chanralens, including 8-MOP, to form an interstrand cross-link of the double helix. While the Watson-Crick hydrogen nel initially in both whole cell (347) and single-channel studies (90, 324, 346, 409) and finally in transepithelial bonding is maintained throughout the double helix, the strength of the hydrogen bond is weakened at the site of short-circuit current measurements (409), albeit at a much reduced affinity (K i of glibenclamide for CFTR of Ç30 cross-linking. Thus the psoralens induce significant changes in the local DNA helix, although there is no im-mM and nM for K ATP ). These results suggested that other known modulators of K ATP might also influence the gating portant effect on the overall helical structure (176). This DNA cross-linking interferes with replication and tran-of CFTR. Based on these observations, we determined the effect of several psoralens on Cl 0 secretion in the T84 cell scription resulting in an immediate inhibition of DNA synthesis and cell proliferation. Although it was initially be-line as well as primary MTE cultures (94). Although 8-MOP failed to induce a Cl 0 secretory response on its own lieved that this inhibition of DNA synthesis was responsible for the therapeutic effect observed, more recent in the T84 cell line, it both potentiated the Cl 0 secretory effect of the muscarinic agonist carbachol as well as inevidence has demonstrated that the angelicins also possess therapeutic potential while failing to form the bifunc-duced a sustained plateau phase to the carbachol response. These results are consistent with the activation tional adducts required to inhibit DNA synthesis (80) . A second photochemical reaction involves the transfer of of an apical membrane Cl 0 conductance by the psoralens in the absence of any change in basolateral K / conducenergy to molecular oxygen resulting in reactive oxygen species and free radicals. This in turn activates the arachi-tance. This paradigm has previously been used to explain the potentiation of a Ca 2/ -mediated agonist responses in donic acid metabolism cascade, resulting in eicosanoid formation. The result of this is erythrema, a known clinical T84 cells by increasing cellular cAMP (23). This hypothesis was evaluated by determining the effect of 8-MOP on manifestation of PUVA therapy (135) .
This ability of the psoralens to intercalate into the Cl 0 secretion after activation of the basolateral membrane K Ca by either the Ca 2/ -ATPase inhibitor thapsigargin or a DNA helix, thereby inhibiting DNA replication, has recently been exploited in designing viral vectors for gene direct pharmacological opener of K Ca 1-EBIO (93, 95). http://physrev.physiology.org/ Downloaded from S133 sponse (94). Finally, in nystatin-permeabilized T84 mono-lated a significant Cl 0 secretory response in both DF508 (2.5 { 0.5 mA/cm 2 ; n Å 11) and wild-type CFTR (7.9 { 0.8 layers, 8-MOP increased apical Cl 0 conductance while having no effect on basolateral K / conductance. The acti-mA/cm 2 ; n Å 17) expressing HBE. To our knowledge, these are the first results demonstrating an effect of a pharmacovation of Cl 0 conductance was insensitive to block by either Cd 2/ , an inhibitor of ClC-2 (334), or TS-TM-Ca-logical opener (NS004, genistein) of CFTR on human CF lix [4] arene, an inhibitor of the outwardly rectifying Cl 0 airway and suggest that native human airway expresses channel (358) . In contrast, the 8-MOP-induced activation sufficient DF508 CFTR at the apical membrane to be modof Cl 0 conductance was inhibited by glibenclamide (94). ulated by pharmacological agonists. As further support This pharmacological profile is consistent with the activa-for this hypothesis, we incubated DF508 HBE cells at tion of CFTR by 8-MOP.
26ЊC for 24 h and determined the effect of 1-EBIO, NS004, These results suggest that the psoralens, which are and genistein on Cl 0 secretion. This treatment is expected clinically useful for a variety of diseases, may be therapeu-to increase the delivery of DF508 CFTR to the apical tically beneficial in CF therapy by increasing apical Cl 0 membrane (89). Under these conditions, the effects of conductance. Indeed, we recently demonstrated that, 1-EBIO, NS004, and genistein on Cl 0 secretion were all after inhibition of basal Na / transport with amiloride, 8-potentiated [1.5 { 0.2 (n Å 4), 2.0 { 0.3 (n Å 7), and 8.3 { MOP stimulates a Cl 0 secretory response in primary cul-2.4 (n Å 6) mA/cm 2 , respectively]. tures of HBE (unpublished observations). Despite these In addition to determining the effect of these ion observations, we have been unable to demonstrate a di-channel modulators on Cl 0 secretion, it will also be imrect activation of CFTR by 8-MOP in excised inside-out portant to evaluate their effects on Na / absorption across patches in the presence of 300 mM ATP with or without human airway. For example, we recently demonstrated PKA (unpublished observations). Also, in Xenopus oo-that Ca 2/ -mediated agonists, including mucosal UTP, are cytes expressing wild-type CFTR, 8-MOP fails to activate potent inhibitors of Na / absorption across CF airway sug-CFTR on its own. These results suggest that CFTR must gesting they may have a dual therapeutic role: 1) the inhibe in an appropriate conformational state for the pso-bition of Na / hyperabsorption associated with CF and ralens to activate the channel.
2) the stimulation of Cl 0 secretion (92). In contrast, we demonstrated that genistein stimulates Na / absorption in human CF airway (92). Also, we found that 1-EBIO stimu-
IV. HUMAN AIRWAY EPITHELIAL STUDIES
lates Na / absorption as expected for a compound that opens basolateral membrane K / channels and thus inIt is clear from the above discussion that several ex-creases the driving force for Na / entry across the apical citing lead compounds have been identified that are capa-membrane (unpublished observations). In contrast, ble of stimulating Cl 0 secretion across human airway. Al-NS004 has no effect on Na / absorption across human CF though we have not evaluated all of these compounds to airway. Thus it will be important to carefully evaluate the determine their ability to modulate Cl 0 secretion across effects of these investigational drugs not in isolation on primary cultures of human CF (DF508: DF508) airway, the intended target (CFTR) but rather in the context of the we have studied several of these, including genistein, transporting epithelium where they may have potentially NS004, and 1-EBIO. The K / channel opener 1-EBIO (1 unwanted effects on alternative targets such as Na / abmM) had no effect on Cl 0 secretion in these cultures sorption. (change in short-circuit current Å 0.06 { 0.08 mA/cm 2 ;
Finally, it will be important in future studies to detern Å 15). In comparison, in wild-type CFTR expressing mine whether these modulators of CFTR stimulate a Cl 0 HBE, 1-EBIO increased short-circuit current by 11.6 { 0.9 secretory response in human airways expressing addimA/cm 2 (n Å 20). Similarly, when added alone, NS004 tional mutations that are normally trafficked to the apical increased short-circuit current by only 0.4 mA/cm 2 (n Å membrane in the intact epithelium (e.g., G551D). As out-13) in DF508 expressing HBE, whereas in wild-type CFTR lined above, pharmacological agonists have been shown expressing HBE, NS004 increased short-circuit current by to activate the G551D mutant in Xenopus oocytes. These 10.8 { 1.7 mA/cm 2 (n Å 18). Forskolin also has little effect studies will be important in determining the CF patients as expected for a CF airway; increasing short-circuit cur-with appropriate genotypes amenable to pharmacological rent by 1.5 mA/cm 2 (n Å 21) compared with 13.7 { 1.2 manipulation by ion channel openers versus those that mA/cm 2 (n Å 116) in wild-type CFTR expressing HBE. will require alternative interventions including chemical However, subsequent to forskolin, NS004 (10 mM) in-chaperones or gene therapy. creased short-circuit current by an additional 2.1 mA/cm
